CTLA-4重回牌桌,和铂医药坐上“C位”

医曜
Feb 23

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。随着2025年诺贝尔生理学或医学奖授予三位专注于调节性T细胞(Treg细胞)研究的免疫学家,曾一度被市场边缘化的CTLA-4靶点再度成为生物医药业界的关注焦点。在此行业风口到来之际,全球药企纷纷加码布局,其中BioNTech公司已将CTLA-4抑制剂Gotistobart列为未来发展的核心重点,而和铂医药也于近期顺利完成新一代CTLA...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10